EKF Diagnostics Holdings plc (LON:EKF - Get Free Report)'s stock price fell 7% during mid-day trading on Saturday . The company traded as low as GBX 23.60 ($0.31) and last traded at GBX 26 ($0.35). 2,281,890 shares changed hands during trading, an increase of 404% from the average session volume of 453,091 shares. The stock had previously closed at GBX 27.95 ($0.37).
EKF Diagnostics Stock Performance
The company has a market cap of £116.76 million, a PE ratio of 19.26 and a beta of 0.57. The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34. The business has a fifty day moving average of GBX 29.18 and a 200-day moving average of GBX 26.59.
EKF Diagnostics (LON:EKF - Get Free Report) last announced its quarterly earnings results on Tuesday, September 16th. The company reported GBX 0.43 earnings per share (EPS) for the quarter. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%. Equities research analysts anticipate that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.
EKF Diagnostics Company Profile
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
